Changes of central macular thickness post intravitreal ranibizumab and its associated factors among diabetic macular oedema patients
Background: Intravitreal Ranibizumab (IVR) which is an anti-vascular endothelial growth factor (anti-VEGF) has become the preferred treatment option to improve the vision of diabetic macular oedema (DMO) patients. IVR acts by inhibits VEGF-A from binding to its receptors, leading to decreased in vas...
| मुख्य लेखक: | |
|---|---|
| स्वरूप: | थीसिस |
| भाषा: | अंग्रेज़ी |
| प्रकाशित: |
2020
|
| विषय: | |
| ऑनलाइन पहुंच: | http://eprints.usm.my/51000/ |